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Previous studies have demonstrated that C3b-coated erythrocytes rosette with
herpes simplex virus I (HSV-I)-infected endothelial, epithelial, and fibroblastic
cells (1-3). Glycoprotein C (gC-1) of HSV-1 was postulated to mediate this
binding because antibodies to gC-I inhibited this reaction (2, 4). Also, cells
infected with HSV-1(MP) (a gC-1- mutant) did not exhibit C3b-dependent rosette
formation, whereas cells infected with HSV-I(MP)6-9A [a derivative of HSV-
1(MP) with a functional gC-1 gene insertion] did form rosettes (4, 5).
The discovery of a viral protein exhibiting C3b binding activity was an
unanticipated finding. Its biologic significance has not been entirely elucidated.
However, with the realization that many C3b- and C4b-binding proteins possess
regulatory roles in the complement cascade and inhibit activation on autologous
tissue (6), it became apparent that such a protein on the virus envelope or on a
virally infected cell could inhibit complement activation. Purified gC-1 has
recently been shown to possess decay-accelerating activity for the alternative
pathway C3 convertase and, by this mechanism, could block the effects of
complement (7). This same functional activity is possessed by two human com-
plement-regulatory proteins, decay-accelerating factor and the C3b/C4b recep-
tor (CR1) (6).
In previous studies, cells infected with HSV-2 as well as cytomegalovirus and
varicella zoster virus failed to form rosettes with C3b-coated erythrocytes, sug-
gesting that these viruses might not encode a C3-binding protein (2, 4). In this
report we confirm by affinity chromatography prior results demonstrating that
gC-1 expressed by HSV-1-infected cells is a C3 binding protein. By this same
methodology we present evidence that gC-2 expressed by HSV-2-infected cells
also binds to human C3. In addition, we show that the presence of gC-1 or gC-2
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in virions provides protection against complement-mediated neutralization of
viral infectivity.
Materials and Methods
Cells and Virus Strains.
￿
HEp-2 and Vero cells, obtained from the American Type
Culture Collection (Rockville, MD), were grown in DMEM supplemented with 10% FCS
and in medium 199 supplemented with 5% FCS, respectively. The virus strains used were
HSV-1(HFEM), a laboratory strain of HSV-1 ; HSV-1(MP), a gC- mutant (8); HSV-I(MP-
6-9A, a derivative of HSV-1(MP) containing a functional gC-1 gene [from strain HSV-
1(F)] inserted in its thymidine kinase gene (9); HSV-1(MP)801-1, a derivative of HSV-
1(MP) containing a functional gC-2 gene [from strain HSV-2(333)] inserted into its
thymidine kinase gene (10); and HSV-2 (G), a low-passage clinical isolate of HSV-2 .
Preparation of Labeled Extracts from Infected Cells. HEp-2 cells (^-1 .5 X 10'
cells/monolayer culture) were inoculated with virus at multiplicity of infections of 10-20
PFU/cell in PBS (10 mM Na2HP04 , 1 .5 mM K2HP04, 140 mM NaCl, 3 mM KCI, 0 .5
MM MgCl2, and 1 mM CaC12, pH 7.4) containing 0.1% glucose and 1 % BSA
(PBS/G/BSA)l . After allowing adsorption of virus for 2 h at 37°C, the inoculum was
removed and replaced with medium 199 containing a radioactive precursor, either f35S]
methionine at 50 ACi/ml (the medium 199 was altered to contain 10% the usual concen-
tration of methionine and supplemented with 10 mM Hepes) or [` QC]glucosamine at 0 .5
ACi/ml . At 18-24 h after addition of virus, extracts of the infected cells were prepared.
The cell monolayers were washed with cold PBS and the cells scraped into PBS. The cell
pellets (^-1 .5 X 10' cells per pellet) were suspended in 2 ml of solubilization buffer (PBS
containing 1 % NP-40, aprotinin at 100 U/ml and, in some cases, 1 % sodium deoxycholate
or I mM PMSF). Nuclei were removed from the cell lysates by low-speed centrifugation,
and the cytoplasmic fractions were frozen at -80°C until use.
Before the affinity chromatography or immunoprecipitation, each solubilized prepara-
tion was thawed, dialyzed at 4°C against PBS (150 mM NaCl, 10 mM K2HP04, 1 .5 mM
NaH2P04, pH 7.4) containing 1 % NP-40, 2 mM PMSF, 1 AM pepstatin, 3 mM EDTA,
and 2 mM iodoacetamide, and then centrifuged at 80,000 g in a Beckman L8-80M
ultracentrifuge for 1 h at 4 °C.
Affinity Chromatography.
￿
Human iC3 and iC4 were coupled to Sepharose 4B via CNBr
activation at 2 mg of iC3 or iC4/ml Sepharose (11). BSA (Sigma Chemical Co., St. Louis,
MO) and human IgG (fraction 11; Miles Scientific, Naperville, IL) were coupled to
Sepharose 4B at 10 mg/ml. Coupling efficiency was >90% . Human C3b was coupled to
thiol-Sepharose as previously reported (12, 13). The protein-Sepharose conjugates were
stored in borate-buffered saline (0.15 M NaCl, 0.2 M H2BO3, pH 8 .0), 1 % NP-40, 0.02%
NaN3. Before use, the Sepharose beads were washed with PBS, 1 % NP-40.
Solubilized preparations of cells were preincubated with BSA- or IgG-Sepharose on a
rotator for 1 h at room temperature. The supernatant was then incubated for 1 h with
control (BSA or IgG) Sepharose or specific (iC3, iC4, C3b) Sepharose . The supernatant
was removed and beads transferred to a polypropylene column (11 ml; Bio-Rad Labora-
tories, Richmond, CA) with 3 ml of a 1 :3 dilution of PBS + 1 % NP-40, 2 mM PMSF. The
conjugated Sepharose was washed three times with 4 ml of a 1 :3 dilution of PBS, 1 % NP-
40, and then eluted with 400 mM NaCl, 1% NP-40. The eluted material was dialyzed
overnight at 4°C against water. After lyophilization and acetone precipitation, the pellet
was resuspended in a reducing sample buffer for gel electrophoresis (0.25 M Tris-base,
2% SDS (wt/vol), 10% glycerine, 10-3% bromphenol blue (wt/wt), 2-ME (5% vol/vol), pH
6.8) and heated at 80 ° C for 5 min.
Immunoprecipitation and SDS-PAGE Analysis. The antibodies used were as follows:
ascitic fluid containing mAb to gC-1 (1173-1, 11474-1, 11475-1, 11512-3, 11529-1) or to
gC-2 (III-188-4, III-211-1, III-596-1) were lyophilized and resuspended to original volume
in PBS, pooling those antibodies specific for the same glycoprotein (14). Ascitic fluid
containing mAb MOPC-21, of unknown specificity, was treated as above and used as
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control. The solubilized preparations of infected cells were first precleared with Staphy-
lococcus aureus protein A (Cowan I Strain; Calbiochem-Behring, La Jolla, CA). This
suspension was centrifuged and the supernatant was removed and incubated with either
specific or nonspecific mAb for 1 h at 4°C. The preparations were then incubated with
protein A for 15 min, washed three times with 1 ml of PBS, 1% NP-40, and the bound
proteins were eluted with sample buffer forelectrophoresis(described above).Thesamples
were heated at 80°C for 5 min, centrifuged, and the supernatant was analyzed by SDS-
PAGE and autoradiography (15).
Neutralization ofViralInfectivity.
￿
In avolume of 2.5 ml, thereaction mixtures contained
virus at 500-1,000 PFU/ml, human serum at a final dilution of 1:15 and, in some
instances, a heat-inactivated rabbit antiserum containing neutralizing antibodies specific
for HSV gD at a final dilution of 1:125. The diluent for all components of the reaction
mixture was PBS/G/BSA. The human serum was either heated to 56°C for 30 min to
inactivate complement components, or was unheated, or was a mixture of heated and
unheated samples. The human serum chosen for use was shown to be free of anti-HSV
antibodies by Western blot analysis and by absence of neutralizing activity in heat-
inactivated samples. The reaction mixtures were prepared on ice and then incubated at
37 °C for 1 h. 1-ml samples were then plated on monolayers of Vero cells in 25-cm2flasks
to permit plaque development in a standard plaque assay.
Results
Identification of C3-binding Proteins from Extracts ofHSV-1- and HSV-2-Infected
Cells. Although published evidence clearly demonstrates that gC-1 is required
for the C3b binding activity of HSV-1-infected cells, the binding of solubilized
gC-1 to C3b or iC3 has not yet been reported. Our first series of experiments
was designed to determine whether gC-1 could bind to iC3-Sepharose columns.
Fig. 1 shows that two polypeptides solubilized from HSV-1(HFEM)-infected cells
bound to the column. These polypeptides could be labeled with either [s5S]-
methionine or ["C]glucosamine, and their M, (110,000-130,000 and 90,000-
95,000) are similar to those of the mature and precursor forms, respectively, of
gC-1 (16, 17). Two lines of evidence demonstrate that the polypeptides bound
to iC3-Sepharose are products of the gC-1 gene. First, the gC- mutant HSV-
1(MP) failed to produce either polypeptide, whereas HSV-1(MP)6-9A produced
both (Fig. 1). The latter virus strain is a derivative of HSV-1(MP) containing an
insertion of a functional gC-1 gene (9). Moreover, in experiments in which the
extract was first exposed to iC3-Sepharose and then immunoprecipitated with
antibodies to gC-1, or vice versa, the quantity of the peptides specifically re-
covered in the second step was markedly depleted (Fig. 1). The mature forms of
gC-1 are heterogeneous in M, due in part to heterogeneity in sialation (17, 18).
It is of interest that, in comparison with the forms of gC-1 in immunoprecipitates,
the iC3-binding material is relatively enriched for the precursor form and the
faster-migrating, least-sialated mature forms of gC-l .
Similar experiments were done with extracts from HSV-2(G)-infected cells. As
shown in Figs. 2 and 3, a glycopeptide of Mr 75,000-85,000 bound to iC3-
Sepharose but not to IgG- or iC4-Sepharose. No iC3-bindingmaterial was isolated
from mock-infected cells. The HSV-2 glycoprotein that is antigenically and
evolutionarily related to gC-1 is designated gC-2 and has an M,. similar to that of
the iC3-binding glycopeptide (19) . Moreover, immunoprecipitation of HSV-2-
infected cell extracts with anti-gC-2, but not anti-gC-1 or MOPC, removed the
iC3-binding glycopeptide (Figs. 3 and 4). Finally, the insertion mutant HSV-1528
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FIGURE 1 .
￿
Autoradiographs of proteins isolated by iC3-affinity chromatography or immu-
noprecipitation from extracts of HSV-1-infected HEp-2 cells . A. Comparison of three HSV-1
strains[HSV-1(HFEM), HSV-I(MP) (gC-1 - mutant) or HSV-I(MP)6-9A (gC-1 recombinant)] .
B. Comparison of proteins isolated by affinity chromatography or immunoprecipitation . Lane
5 represents the proteins isolated by immunoprecipitation with antibodies to gC-1 . In lanes2-
4, the preparation was subjected to sequential affinity chromatography . The last supernatant
was then immunoprecipitated with antibodies to gC-1 [s5S]methionine (lane 6) . AC, affinity
chromatography; IP, immunoprecipitation ;M, mature form of gC-1 ; P, precursor form of gC-
1 ; agC-1, mAb to gC-I .
1(MP)801-1 produces iC3-binding material of the appropriate M, . This mutant
is a derivative of HSV-1(MP) containing an insertion of a functional gC-2 gene .
For viral extracts containing gC-1 or gC-2, affinity chromatography with C3b-
thiol-Sepharose produced identical results to that with iC3 (not shown) .
gC Expression and Complement-mediated Neutralization .
￿
Todetermine whether
presence of gC-1 or gC-2 in the virus might influence complement-mediated
neutralization of infectivity, neutralization studieswere done with the gC- mutant
HSV-1(MP) and the recombinants expressing gC-1 or gC-2 [HSV-1(MP)6-9A
and HSV-1(MP)801-l] . This particular set of viruses was chosen because all
virion components except gC are identical for the three viruses, and because the
two recombinants produce comparable quantities of gC-1 and gC-2 . These
isogenic viruses, differing only in their expression of gC, were incubated with
human serum from a seronegative individual in the presence or absence of rabbit
anti-HSV antibodies . Various proportions of heated and unheated human serum
were present in each reaction mixture such that concentrations ofactive comple-McNEARNEY ET AL .
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FIGURE 2. Autoradiograph of proteins isolated by affinity
chromatography from extracts HSV-2- or mock-infected HEp-
2 cells incubated with iC3- or IgG-Sepharose, labeled with ["CI
-glucosamine . Arrowhead, gC-2 .
FIGURE 3 .
￿
Autoradiograph of pro-
teins isolated by affinity chromatog-
raphy or immunoprecipitation from
extracts of HSV-2-infected HEp-2
cells . The samples in lanes 2-4 were
first subjected to immunoprecipita-
tion before being incubated with iC3-
Sepharose . In lanes 7and 8, the sol-
ubilized preparation was first prein-
cubated with IgG- or BSA-Sepharose
before being incubated with iC3- or
iC4-Sepharose . In lane 10 the solu-
bilized preparation was heated in
sample buffer and applied to the gel
to demonstrate the major radiola-
beled bands, labeled with ["Clglu-
cosamine . agC-2, agC-1, and MOPC,
mAb to gC-1, gC-2,andof unknown
specificity, respectively . Arrowhead,
gC-2 . Note that antibodies to gC-2
specifically remove the iC3-binding
protein .
ment components differed while concentrations of total serum protein remained
constant . Fig . 5A shows that human complement enhanced the neutralization
mediated by anti-HSV antibodies in a dose-dependent fashion, but only for the
gC- mutant HSV-1(MP) . The recombinant viruses expressing gC-1 or gC-2
appeared to be protected from the neutralizing effects of complement . Similar
results were obtained when the three virus strains were incubated with human
serum in the absence of anti-HSV antibodies (Fig . 5B), suggesting that there is
also antibody-independent neutralization by complement .1530
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FIGURE 4 .
￿
Autoradiograph of proteins isolated by affinity chromatography or immunopre-
cipitation from extracts of HSV-I(MP)80I-1-infected HEp-2 cells. A. Comparison of the
proteins isolated by the two procedures . B. Samples in lanes 8 and 9 were first subjected to
immunoprecipitation, and then the supernatants were incubated with iC3-Sepharose . In lane
5, the solubilized preparation was heated in sample buffer to demonstrate the major radiola-
beled bands . Definitions are identical to those of Figs . 1 and 3 . Note that the bands isolated
by either procedure align . Label is [sSS]methionine .
ml of SERUM ADDED (1 "3 Dilution)
FIGURE 5 .
￿
Effects of human complement on
HSV infectivity . Unheated and heated samples
of human serum (diluted 1 :3) were mixed in
the proportions indicated for addition to the
neutralization reaction mixtures as described in
uc-1 the text . Anti-HSV neutralizing antibodies
were present(A) or absent (B). The values pre-
.C" _2 sented are the average of duplicate determina-
tions (the values taken as 100% range from 52
to 533) . The concentration of anti-HSV serum
used in A was chosen so that the number of
PFUs obtained in the presence of anti-HSV
Noac
￿
serum plus heated human serum was 20-50%
of the number obtained in the presence of
heated human serum alone . The virus strains
0.4
￿
5
￿
used were the gC- mutant HSV-1(MP) or re-
0. '
￿
°
￿
combinants derived from HSV-I(MP) by inser-
tion of a functional gC-1 or gC-2 gene . This
study is representative of six similar experi-
ments .McNEARNEY ET AL.
￿
153 1
Discussion
Several prior reports have established that Cab-coated red blood cells form
rosettes with HSV-1-infected cells (1-5). In those reports, multiple cell lineswere
used, and C3b-dependent rosette formation correlated with the expression of
gC-1. Pretreatment of these cells with mAb to gC-1 inhibited this reaction .
Moreover, purified gC-1 exhibited decay-accelerating activity for the C3 conver-
tase of the alternative pathway (7).
The use of iC3 affinity chromatography has contributed some additional
insightsinto the nature ofthis interactionbetween activation fragments ofhuman
C3 and gC-1 . First, this work provides further evidence that gC of HSV-1 is a
C3-binding protein. iC3 andC3bare functionally equivalent activation fragments
of C3 (20, 21), and we have obtained binding to both. In addition, both the
mature and precursor formsofgC-1 bind to iC3-Sepharose. In fact, theprecursor
form and less sialylated mature forms may bind preferentially. The gC-1 precur-
sor has N-linked sugars of a high mannose type, and in the mature form these
are converted to complex carbohydrate moieties in the Golgi (18, 22). Also, 0-
linked sugars are attached to gC-1 as the protein moves through the Golgi (18,
23, 24). These data suggest that the attachment of the 0-linked sugars or
conversion of high mannose to complex oligosaccharides alters the binding of
gC-1 to iC3. Of interest in this regard is that pretreatment of HSV-1-infected
cells with neuraminidase increases their ability to form rosettes (3, 5). These data
are also of note relative to human CR1, a C3b/C4b complement receptor and
regulatory protein that may be antigenically (3) as well as functionally related to
gC-1 . Carbohydrate has been shown to be important to the stability, transport,
and binding efficiency ofhuman CR1 (25).
A new finding in this report is that HSV-2, as well as HSV-1, expresses a C3b
binding glycoprotein, despite previous indications that HSV-2 might not exhibit
this activity (4, 5). In the studies herein, gC-2 from two viral strains, a low-
passage clinical isolate [HSV-2(G)] and gC-2, derived from a laboratory strain
[HSV-2(333)] both boundto iC3-Sepharose. Thegenesfor gC-1 and gC-2 occupy
colinear positions on their respective viral genomes (10) and are homologous in
sequence (26, 27). The glycoproteins specified by these genes are quite different
in size, however, in part because gC-1 contains a stretch of 27 amino acids near
its NH2-terminus that are not present in gC-2 (26, 27). Moreover, the number
ofantigenic determinants shared by the two glycoproteins seems to be limited in
comparison with the unique antigenic determinants (14, 19, 28, 29). Although
these two homologous glycoproteins have diverged with time more than some
of the other homologous HSV-1 and HSV-2 glycoproteins, it appears that they
retain a common affinity for C3b and very likely also retain common activities
associated with this binding activity. Comparisons of the deduced amino acid
sequences for gC-1 and gC-2 reveal the presence ofhighly conserved regions. It
remains to be determined whether the C3b-binding domain can be mapped to
any of these conserved domains. To further investigate this issue, the deduced
protein sequences of gC-1 and gC-2 have been compared with the sequences of
members of the human C3b/C4b binding protein family (6). The comparisons
indicate the presence ofnumerous homologous regions between gC-1, gC-2, and
the human proteins (V. M. Holers, unpublished data). These results suggest an1532
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evolutionary relationship between viral glycoprotein C and this family. Experi-
ments are currently underway to determine whether these specific peptide
sequences are functionally relevant to the binding ofgC-1 or gC-2 to C3.
It is unclear why cells infected with HSV-I but not with HSV-2 express C3b-
binding activity on their surfaces as detected by the rosette assay. Considering
their amino acid homology, and in view of this study that gC-2 can bind to C3,
one would expect HSV-2-infected cells to rosette with C3-coated erythrocytes.
Several factors that affect rosette formation, such as surface density ofreceptors,
membrane mobility, and cytoskeletal interactions may not be optimal for HSV-
2-infected cells. For example, HSV-2 produces less gC-2 in cultures of cells in
comparison with amounts produced by the recombinant HSV-1(MP)801-1 (10)
or amounts of gC-I produced by HSV-I (P. Spear, unpublished data). One
consequence may be reduced surface density of receptors in cultured cells
infected with HSV-2. It is also possible that differences in glycosylation between
gC-I and gC-2 may alter tertiary structure and may in part be responsible for
the failure of HSV-2-infected cells to rosette with C3b-coated erythrocytes.
Pretreatment with neuraminidase did not enhance rosetting by HSV-2-infected
cells (5), but possibly further manipulation of the carbohydrate moieties would
result in successful rosetting studies. This study demonstrates that the apparent
absence of C3b-binding activity on the surfaces of HSV-2-infected cells cannot
be explained by the failure of HSV-2 to express a C3b-binding glycoprotein.
A second observation of interest in our studies concerns the protection against
complement-mediated viral neutralization by gC-1 and gC-2. In these neutrali-
zation assays, mutant [HSV-1(MP)] and recombinant strains [HSV-1(MP)6-9A
andHSV-I(MP)801-1] were compared withrespect to sensitivitytoneutralization
by complement in the presence or absence of anti-HSV antibody. The use of
these recombinant strains allowed direct assessment ofthe effects ofgC-1 or gC-
2 expression against the common genetic background of the gC- viral mutant.
In this study, as outlined in Fig. 5, the polyclonal anti-gD serum caused some
neutralization in the absence of a complement source, and was used at a
concentration that neutralized ^-50% of input virus. These studies suggest that
gC-I and gC-2 provide protection against complement-mediated viral neutrali-
zation in the presence of antibody. Also, in the absence of antiviral antibody,
fresh but not heated serum enhanced neutralization to a greater extent for the
gC- mutant compared with the gC-1' and gC-2+ strains.
In the experimental system without antibody, the alternative complement
pathway would be operative, and is likely to be responsible for viral neutraliza-
tion. The protection provided by gC-I and gC-2 could be accounted for by the
observation that they promote decay acceleration of the alternative pathway
convertase, as has been directly shown for gC-1 (7). The alternative pathway
convertase is a bimolecular enzyme complex that cleaves C3 to C3b, and C3b is
the major opsonic fragment of the complement system. Cleavage of C3 is also
necessary to initiate the lytic complex. By preventing the formation of and
accelerating the decay of already-formed complexes, gC-1, and by analogy gC-
2, could inhibit neutralization ofthe virus by the alternative complement path-
way. The alternative complement pathway is one of the host's primary means of
controlling infections before and during the development ofimmunity (30), andMcNEARNEY ET AL.
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the data suggest that gC-1 and gC-2 impede immunosurveillance of this system
by interfering with the complement cascade at the critical convertase step of the
alternative pathway. Complement enhancement of antibody-mediated neutrali-
zation was also less apparent for the gC-1' and gC-2+ strains than for the gC-
strain. In this system both the classical andalternative pathway couldbe important
in viral neutralization. It is not clear whether the decay acceleration of the
alternative pathway C3 convertase is entirely responsible for this effect or
whether other effects also result from the C3-binding activity of gC-1 and gC-2.
In summary, the viral synthesis of Cab-binding glycoproteins such as gC-1 and
gC-2 represents one of several mechanisms by which the herpes simplex viruses
may evade the immune system. Both the viruses and virally infected cells are
coated with these proteins,which areanalogousin function andpossibly structure
to complement-regulatory proteins that protect host tissue from complement-
mediated damage (6). Manipulation of the host's immune system should result
in a survival advantage for the virus. Similar means to abrogate the activation of
complement in the host may have evolved in other microorganisms as an
adaptation to enhance infectivity.
Summary
Cells infected with herpes simplex virus type 1 (HSV-1) form rosettes with
C3b-coated erythrocytes, whereas cells infected with herpes simplex virus type 2
(HSV-2) or other herpes viruses do not. It was reported that glycoprotein C of
HSV-1 (gC-1) mediates the binding of C3b-coated erythrocytes to infected cells
and has regulatory (decay-accelerating) activity for the alternative pathway C3
convertase of human complement. We show here that solubilized gC-1 binds to
iC3-Sepharose affinity columns. We also report that solubilized gC-2, the genet-
ically related glycoprotein specified by HSV-2, binds to iC3-Sepharose . mAb
specific for gC-1 or gC-2 and mutant viral strains were used to identify the C3-
binding glycoproteins . In other experiments, HSV-1 mutant strains and recom-
binants, differing only in their expression of gC, were tested for sensitivity to
neutralization by human complement in the presence or absence of antibodies
specific for HSV gD. In either case the gC- strain was most sensitive. Expression
of gC-1 or gC-2 by isogenic insertion mutants provided protection against
complement-mediated neutralization. These results indicate that the genetically
and structurally related gC-1 and gC-2 share the functional activity of binding
to human C3 and enhance viral infectivity.
We thank Ms. Pat Stewart and Mrs. Lorraine Whiteley for their excellent secretarial
efforts.
Receivedfor publication 11 June 1987 and in revisedform 4 August 1987.
References
1. Cines, D. B., A. P. Lyss, M. Bina, R. Corkey, N. A. Kefalides, and H. M. Friedman.
1982. Fc and C3 receptors induced by herpes simplex virus on cultured endothelial
cells. J. Clin. Invest. 69:123 .
2. Smiley, M. L., J. A. Hoxie, and H. M. Friedman. 1985. Herpes simplex virus type 11534
￿
COMPLEMENT-BINDING PROTEINS OF HERPES SIMPLEX
infection of endothelial, epithelial and fibroblast cells induces a receptor for C3b. J.
Immunol. 134:2673.
3. Kubota, Y., T. A. Gaither, J . Cason, J. J. O'Shea, and T. J. Lawley. 1987 . Character-
ization o£ the C3 receptor induced by herpes simplex virus type 1 infection of human
epidermal, endothelial and A431 cells. J. Immunol. 138:1137.
4. Friedman, H . M., G. H. Cohen, R. J. Eisenberg, C. A. Seidel, and D. B. Cines. 1984.
Glycoprotein C of herpes simplex virus 1 acts as a receptor for C3b complement
component on infected cells. Nature (Lond.). 309:633.
5. Smiley, M. L., and H. M. Friedman. 1985 . Binding of complement component C3b
to glycoprotein C is modulated by sialic acid on herpes simplex virus type I infected
cells. J. Virol. 55:857.
6. Holers, V. M., J. L . Cole, D. M. Lublin, T. Seya, and J . P. Atkinson. 1985. Human
C3b and C4b-regulatory proteins: a new multigene family. Immunol. Today. 6 :188 .
7. Fries, L. F., H. M. Friedman, G. H. Cohen, R. J. Eisenberg, C. H. Hammer, and M.
M . Frank. 1986. Glycoprotein C of herpes simplex virus I is an inhibitor of the
complement cascade.J. Immunol. 137:1636.
8 . Draper, K. G., R. H. Costa, G. T.-Y. Lee, P. G. Spear, and E. K. Wagner. 1984. The
molecular basis of the glycoprotein C negative phenotype herpes simplex virus type
1 macroplaque strain. J. Virol. 51 :578 .
9. Lee, G. T.-Y., K. L. Pogue-Geile, L. Pereira, and P. G. Spear. 1982 . Expression of
HSV gC from a DNA fragment inserted into the thymidine kinase gene of this virus.
Proc. Natl. Acad. Sci. USA. 79:6612.
10. Zezulak, K. M., and P. G. Spear. 1984. Mapping of the structural gene for the herpes
simplex virus type 2 counterpart of herpes simplex virus type 1 glycoprotein C and
identification of a type 2 mutant which does not express this glycoprotein. J. Virol.
49 :741 .
11 . Dykman, T. R., J. L. Cole, K. Iida, and J. P. Atkinson. 1983 . Polymorphism of human
erythrocyte C3b/C4b receptor. Proc. Natl. Acad. Sci. USA. 80:1698.
12 . Cole, J. L., G. A. Housley, Jr., T. R. Dykman, R. P. MacDermott, and J. P. Atkinson.
1985. Identification of an additional class of C3-building membrane proteins of
human peripheral blood leukocytes and cell lines. Proc. Natl. Acad. Sci. USA. 82:859.
13 . Iida, K., L. Nadler, and V. Nussenzweig. 1983. Identification of the membrane
receptor for the complement fragment Cad by means of a monoclonal antibody. J.
Exp. Med. 158:1021 .
14. Para, M. F., M. L. Parish, A. G. Noble, and P. G. Spear. 1985 . Potent neutralizing
activity associated with antiglycoprotein D specificity among monoclonal antibodies
selected for binding to herpes simplex virions. J. Virol. 55:483.
15 . Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature (Lond.). 227 :680.
16 . Spear, P. G. 1976. Membrane proteins specified by herpes simplex viruses. 1 .
Identification of four glycoprotein precursors and their products in type I infected
cells. J. Virol. 17 :991 .
17 . Cohen, G. H., D. Long, and R. J. Eisenberg. 1980. Synthesis and processing of
glycoproteins gD and gC of herpes simplex virus type 1 . J. Virol. 36:429.
18 . Johnson, C. C., and P. G. Spear. 1983. 0-linked oligosaccharides are acquired by
herpes simplex virus glycoproteins in the Golgi apparatus. Cell. 32 :987 .
19. Zezulak, K. M., and P. G. Spear. 1984 . Characterization of a herpes simplex virus
type 2 75,000-molecular weight glycoprotein antigenically related to herpes simplex
type I glycoprotein C.J. Virol. 47 :553.
20. Dixit, R., R. Schneider, S. K. Law, A. Kulczycki, and J. P. Atkinson. 1982 . LigandMcNEARNEY ET AL.
￿
1535
binding specificity of a rabbit alveolar macrophage receptor for C3b. J. Biol. Chem.
257:1595.
21 . Schreiber, R. D., M. K. Pangburn, and H. J. Muller-Eberhard. 1981 . C3 modified at
the thioester site: acquisition of reactivity with cellular C3b receptors. Biosci. Rep.
1 :873.
22. Wenske, E. A., M. W. Bratton, and R. J. Courtney. 1982 . Endo-,B-N-acetylglucosa
minidase H sensitivity of precursors to herpes simplex virus type 1 glycoproteins gB
and gC . J. Virol. 44:241 .
23. Olofsson, S., 1. Sjoblom, M. Lundstrom, S. Jeansson, and E. Lycke. 1983. Glycopro-
tein C of HSV type 1 : Characterization of O-linked oligosaccharides. J. Gen. Virol.
64:2735.
24. Dall'Olio, F., N . Malagolini, V. Speziali, G. Campadelli-Fiume, and F. Serafini-Cessi.
1985 . Sialylated oligosaccharides O-glycosidically linked to glycoprotein C from
herpes simplex virus type 1 . J. Virol. 56:127 .
25. Lublin, D. M ., R. C. Griffith, and J. P. Atkinson. 1986. Influence of glycosylation on
allelic and cell specific M, variation, receptor processing and ligand binding of the
human complement C3b/C4b receptor. J. Biol. Chem. 261 :5736.
26. Dowbenko, D. J., and L. A . Lasky. 1984. Extensive homology between the herpes
simplex virus type 2 glycoprotein F gene and the herpes simplex virus type 1
glycoprotein C gene. J. Virol. 52:154.
27. Swain, M . A ., R. W. Peet, and D . A. Galloway. 1985 . Characterization of the gene
encoding herpes simplex virus type 2 glycoprotein C and comparison with type 1
counterpart.J. Virol. 53:561 .
28. Zweig, M ., S. D. Showalter, S. V. Bladen, C. J. Heilman, Jr., and B. Hampar. 1983.
Herpes simplex virus type 2 glycoprotein gF and type 1 glycoprotein gC have related
antigenic determinants. J. Virol. 47 :185.
29. Zweig, M ., S. D. Showalter, D. J . Simms, and B. Hampar. 1984. Antibodies to a
synthetic oligopeptide that reacts with HSV type 1 and 2 glycoprotein C. J. Virol.
51 :430.
30. Cooper, N. R., and G. R. Nemerow. 1983 . Complement, viruses and virus-infected
cells. Springer Semin. Immunopathol. 6:327.